当前位置: X-MOL 学术Mol. Cancer Ther. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
CCL26 participates in the PRL-3-induced promotion of colorectal cancer invasion by stimulating tumor-associated macrophage infiltration
Molecular Cancer Therapeutics ( IF 5.3 ) Pub Date : 2017-10-19 , DOI: 10.1158/1535-7163.mct-17-0507
Qiusheng Lan 1 , Wei Lai 1 , Yujie Zeng 1 , Lu Liu 1 , Shoufeng Li 2 , Shaowen Jin 1 , Yang Zhang 3 , Xingxi Luo 1 , Heyang Xu 1 , Xiangan Lin 4 , Zhonghua Chu 1
Affiliation  

Both phosphatase of regenerating liver-3 (PRL-3) and tumor-associated macrophages (TAM) influence cancer progression. Whether PRL-3 plays a critical role in colorectal cancer invasion and metastasis by inducing TAM infiltration remains unclear. In the current study, we investigated the effects of chemokine ligand 26 (CCL26) on TAM infiltration and colorectal cancer invasion and the underlying mechanism in colorectal cancer cells by overexpressing or silencing PRL-3. We found that PRL-3 upregulated CCL26 expression correlatively and participated in cell migration, according to the results of gene ontology analysis. In addition, IHC analysis results indicated that the PRL-3 and CCL26 levels were positively correlated and elevated in stage III and IV colorectal cancer tissues and were associated with a worse prognosis in colorectal cancer patients. Furthermore, we demonstrated that CCL26 induced TAM infiltration by CCL26 binding to the CCR3 receptor. When LoVo-P and HT29-C cells were cocultured with TAMs, CCL26 binding to the CCR3 receptor enhanced the invasiveness of LoVo-P and HT29-C cells by mobilizing intracellular Ca2+of TAMs to increase the expression of IL6 and IL8. In addition, IHC results indicated that protein levels of CCR3 and TAMs counts were higher in stage III and IV colorectal cancer tissues and correlated with CCL26. Moreover, similar results were observed in vivo using mice injected with LoVo-P and HT29-C cells. These data indicate that PRL-3 may represent a potential prognostic marker that promotes colorectal cancer invasion and metastasis by upregulating CCL26 to induce TAM infiltration. Mol Cancer Ther; 17(1); 276–89. ©2017 AACR.

中文翻译:

CCL26通过刺激肿瘤相关巨噬细胞浸润参与PRL-3诱导的结直肠癌侵袭促进

再生肝 3 磷酸酶 (PRL-3) 和肿瘤相关巨噬细胞 (TAM) 都会影响癌症进展。PRL-3 是否通过诱导 TAM 浸润在结直肠癌侵袭和转移中起关键作用尚不清楚。在目前的研究中,我们通过过表达或沉默 PRL-3 研究了趋化因子配体 26 (CCL26) 对 TAM 浸润和结直肠癌侵袭的影响以及结直肠癌细胞中的潜在机制。根据基因本体分析结果,我们发现PRL-3相关上调CCL26表达并参与细胞迁移。此外,IHC分析结果表明,PRL-3和CCL26水平在III期和IV期结直肠癌组织中呈正相关并升高,并且与结直肠癌患者的预后较差有关。此外,我们证明了 CCL26 通过 CCL26 与 CCR3 受体结合诱导 TAM 浸润。当 LoVo-P 和 HT29-C 细胞与 TAM 共培养时,CCL26 与 CCR3 受体的结合通过动员 TAM 的细胞内 Ca2+ 来增加 IL6 和 IL8 的表达来增强 LoVo-P 和 HT29-C 细胞的侵袭性。此外,IHC 结果表明 CCR3 和 TAMs 计数的蛋白质水平在 III 期和 IV 期结直肠癌组织中较高,并与 CCL26 相关。此外,使用注射了 LoVo-P 和 HT29-C 细胞的小鼠在体内观察到类似的结果。这些数据表明,PRL-3 可能是一种潜在的预后标志物,通过上调 CCL26 诱导 TAM 浸润来促进结直肠癌的侵袭和转移。摩尔癌症治疗; 17(1); 276-89。©2017 AACR。我们证明了 CCL26 通过 CCL26 与 CCR3 受体结合诱导 TAM 浸润。当 LoVo-P 和 HT29-C 细胞与 TAM 共培养时,CCL26 与 CCR3 受体的结合通过动员 TAM 的细胞内 Ca2+ 来增加 IL6 和 IL8 的表达来增强 LoVo-P 和 HT29-C 细胞的侵袭性。此外,IHC 结果表明 CCR3 和 TAMs 计数的蛋白质水平在 III 期和 IV 期结直肠癌组织中较高,并与 CCL26 相关。此外,使用注射了 LoVo-P 和 HT29-C 细胞的小鼠在体内观察到类似的结果。这些数据表明,PRL-3 可能是一种潜在的预后标志物,通过上调 CCL26 诱导 TAM 浸润来促进结直肠癌的侵袭和转移。摩尔癌症治疗; 17(1); 276-89。©2017 AACR。我们证明了 CCL26 通过 CCL26 与 CCR3 受体结合诱导 TAM 浸润。当 LoVo-P 和 HT29-C 细胞与 TAM 共培养时,CCL26 与 CCR3 受体的结合通过动员 TAM 的细胞内 Ca2+ 来增加 IL6 和 IL8 的表达来增强 LoVo-P 和 HT29-C 细胞的侵袭性。此外,IHC 结果表明 CCR3 和 TAMs 计数的蛋白质水平在 III 期和 IV 期结直肠癌组织中较高,并与 CCL26 相关。此外,使用注射了 LoVo-P 和 HT29-C 细胞的小鼠在体内观察到类似的结果。这些数据表明,PRL-3 可能是一种潜在的预后标志物,通过上调 CCL26 诱导 TAM 浸润来促进结直肠癌的侵袭和转移。摩尔癌症治疗; 17(1); 276-89。©2017 AACR。
更新日期:2017-10-19
down
wechat
bug